Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial

March 9, 2012

Speaker: Shunichi Homma, MD

Friday, April 27, 2012

12:30 p.m. – 12:45 p.m.

Biographical Information:

Dr. Homma is the Margaret Milliken Hatch Professor of Medicine at the Columbia University Medical Center, where he serves as the Associate Chief of Cardiology Division as well as the Director of Noninvasive Cardiac Imaging. He is a graduate of Dartmouth College, and Albert Einstein College of Medicine.  He completed internal medicine residency at the Montefiore Medical Center, and cardiology fellowship training at Massachusetts General Hospital and Columbia–Presbyterian Medical Center. Dr. Homma has been a founding board member of AHA Heritage affiliate, American Society of Echocardiography, and serves or has served on various guideline committees including those for American Academy of Neurology, American Society of Echocardiography and European Heart Failure Society. His research interests center around echocardiographically detected embolic risk factors and treatment strategies for these findings. Dr. Homma has published extensively on such risk factors as PFO, aortic plaque and valvular strands.  Most recently, he has been the Clinical PI for NIH–funded Warfarin Aspirin Reduced Cardiac Ejection Fraction Study (WARCEF), an 11 country international study to compare warfarin and aspirin in patients with reduced LVEF in sinus rhythm.

 email to a friend  |   print